Acurx Pharmaceuticals (NASDAQ: ACXP) reported a net loss of $2.3 million for the second quarter ended June 30, 2026, widening slightly from the $2.2 million loss recorded in the same period last year. The company’s cash position strengthened to $10.7 million, up from $7.6 million at year-end 2025, supported by recent capital raises.

Financial Performance

The quarterly loss translated to $0.53 per diluted share, a significant improvement in per-share metrics compared to $1.89 per diluted share in Q2FY25, driven by share dilution from new issuances. For the first half of FY26, the company logged a net loss of $3.9 million ($1.13 per diluted share) against a $4.4 million loss ($4.01 per diluted share) in the prior year’s first half.

Research and development expenses rose to $1.1 million in Q2FY26 from $0.5 million in Q2FY25, an increase of $0.6 million. This jump was driven by a $0.3 million rise in manufacturing costs and a $0.3 million increase in consulting fees, linked to the new recurrent C. difficile infection (CDI) trial program. Conversely, general and administrative expenses fell by $0.5 million to $1.2 million, aided by reductions in professional fees, legal costs, and share-based compensation.

What the Numbers Show

While the absolute net loss widened marginally, the loss per share contracted sharply due to significant share dilution. The company raised approximately $2.5 million in gross proceeds during the quarter through a registered direct offering and its equity line of credit. This capital injection, combined with a larger $7.1 million registered direct offering closed in April 2026, ensured sufficient funding for operations for at least one year and the upcoming Pathfinder trial.

Clinical and Regulatory Updates

Acurx secured conditional FDA acceptance for the brand name CFezi for Ibezapolstat. The company received FDA guidance supporting a single Phase 3 trial (IBEZ ASPIRE) for acute CDI, contingent on robust data. Enrollment for the 20-patient Pathfinder study in recurrent CDI is expected to begin in Q4 2026.

Additionally, Acurx renewed its partnership with Leiden University Medical Center to advance DNA Pol3C inhibitors. Preclinical data presented at the 35th Congress in Munich indicated that these novel antibiotics maintain gut microbial diversity while reducing MRSA tissue burden, distinct from existing treatments like linezolid.

Acurx Pharmaceuticals filed a prospectus with the US Securities and Exchange Commission (SEC) for an offering valued at $1.5 million. The filing indicates the company’s intent to raise capital through this specific corporate action.

The document was submitted as part of the regulatory process required for public offerings in the United States. No further financial details, such as use of proceeds or share count, were disclosed in the provided data.

Filing Details

The filing serves as the primary disclosure for this transaction under current regulatory requirements.